AR088483A1 - Proceso para preparar derivados de quinolina - Google Patents

Proceso para preparar derivados de quinolina

Info

Publication number
AR088483A1
AR088483A1 ARP120103944A AR088483A1 AR 088483 A1 AR088483 A1 AR 088483A1 AR P120103944 A ARP120103944 A AR P120103944A AR 088483 A1 AR088483 A1 AR 088483A1
Authority
AR
Argentina
Prior art keywords
formula
compound
alkyl
quinoline derivatives
cyclopropan
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR088483A1 publication Critical patent/AR088483A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/22Oxygen atoms attached in position 2 or 4
    • C07D215/233Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/58Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/57Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/59Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
ARP120103944 2011-10-20 2012-10-22 Proceso para preparar derivados de quinolina AR088483A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161549312P 2011-10-20 2011-10-20

Publications (1)

Publication Number Publication Date
AR088483A1 true AR088483A1 (es) 2014-06-11

Family

ID=47146705

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103944 AR088483A1 (es) 2011-10-20 2012-10-22 Proceso para preparar derivados de quinolina

Country Status (23)

Country Link
US (3) US9365516B2 (https=)
EP (1) EP2768796B1 (https=)
JP (2) JP6208140B2 (https=)
KR (1) KR102075371B1 (https=)
CN (2) CN104395284A (https=)
AR (1) AR088483A1 (https=)
AU (2) AU2012325768B2 (https=)
BR (1) BR112014009302B1 (https=)
CA (1) CA2852771C (https=)
DK (1) DK2768796T3 (https=)
EA (1) EA031485B1 (https=)
ES (1) ES2765013T3 (https=)
GE (1) GEP20207110B (https=)
HU (1) HUE048023T2 (https=)
IL (1) IL232139A (https=)
IN (1) IN2014CN02971A (https=)
MX (1) MX343288B (https=)
PL (1) PL2768796T3 (https=)
PT (1) PT2768796T (https=)
TW (2) TWI619694B (https=)
UA (1) UA116876C2 (https=)
WO (1) WO2013059788A1 (https=)
ZA (1) ZA201402579B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) * 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CA2907334C (en) 2013-03-15 2021-12-07 Exelixis, Inc. Metabolites of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
CN104649969B (zh) * 2013-11-22 2019-02-12 广东东阳光药业有限公司 一种替尼类药物的盐及其制备方法
BR112016018450A2 (pt) 2014-02-14 2018-09-18 Exelixis Inc formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, processos de preparo e métodos de uso
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
MX382904B (es) 2014-08-05 2025-03-13 Exelixis Inc Combinaciones de fármacos para tratar mieloma múltiple.
WO2017036405A1 (zh) * 2015-09-02 2017-03-09 陈昆锋 具有蛋白酪氨酸磷酸酶shp-1激动剂活性的化合物
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN109836382B (zh) * 2017-11-29 2021-11-05 江苏豪森药业集团有限公司 苹果酸卡博替尼及其中间体的制备方法
CN117402114A (zh) 2018-01-26 2024-01-16 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
TWI831259B (zh) 2018-06-15 2024-02-01 漢達生技醫藥股份有限公司 包含達沙替尼十二烷基硫酸鹽組合物的膠囊
CN115461328B (zh) 2020-04-30 2025-11-07 埃克塞里艾克西斯公司 用于制备激酶抑制剂的方法
CN112142619B (zh) * 2020-10-20 2023-01-10 浙江工业大学 一种1,1-环丙烷二羧酸酰胺类化合物及其制备方法和应用
CA3213086A1 (en) * 2021-03-24 2022-09-29 Ramakrishna Parameshwar Bhat Process for preparation of cabozantinib
WO2024111001A1 (en) * 2022-11-25 2024-05-30 Msn Laboratories Private Limited, R&D Center Crystalline forms of n-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide fumarate and process for its preparation
WO2024163400A1 (en) 2023-01-31 2024-08-08 Handa Oncology, Llc Improved cabozantinib compositions and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
PL2101759T3 (pl) 2006-12-14 2019-05-31 Exelixis Inc Sposoby stosowania inhibitorów MEK
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
WO2009136663A1 (en) * 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
AR075084A1 (es) * 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
JP5486606B2 (ja) 2008-11-13 2014-05-07 エクセリクシス, インク. キノリン誘導体の調製方法
US20130030172A1 (en) 2008-12-04 2013-01-31 Exelixis, Inc. Methods of Preparing Quinoline Derivatives
NZ779754A (en) * 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102510855B (zh) 2009-07-17 2015-11-25 埃克塞里艾克西斯公司 N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1,1-二甲酰胺的晶形
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2011224203A1 (en) 2010-03-12 2012-10-04 Exelixis, Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin -4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl] -N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EA030435B1 (ru) 2010-07-16 2018-08-31 Экселиксис, Инк. ТАБЛЕТКА, СОДЕРЖАЩАЯ МОДУЛЯТОР c-MET В ФОРМЕ КРИСТАЛЛИЧЕСКОЙ L-МАЛАТНОЙ СОЛИ (ВАРИАНТЫ), СПОСОБ ЕЕ ПРОИЗВОДСТВА И СПОСОБ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКОГО ЗАБОЛЕВАНИЯ С ЕЕ ИСПОЛЬЗОВАНИЕМ
US20140186407A9 (en) 2010-07-16 2014-07-03 Exelixis Inc. C-Met Modulator Pharmaceutical Compositions
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス, インク. 去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬
MX352926B (es) 2010-09-27 2017-12-14 Exelixis Inc Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis osteoblasticas en los huesos.
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
MX2013012695A (es) 2011-05-02 2014-03-27 Exelixis Inc Metodo para el tratamiento del cancer y el dolor por cancer de hueso.
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用pi3k/mtor吡啶並嘧啶酮抑制劑及苯達莫司汀及/或利妥昔單抗治療惡性血液疾病之組合療法
EP2758057B1 (en) 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
CN104395284A (zh) 2011-10-20 2015-03-04 埃克塞里艾克西斯公司 制备喹啉衍生物的方法
IN2014CN04067A (https=) 2011-11-08 2015-10-23 Exelixis Inc
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス, インク. 肺腺癌の治療で使用するためのmet、vegfr、およびretの阻害剤

Also Published As

Publication number Publication date
CN104395284A (zh) 2015-03-04
BR112014009302A2 (pt) 2017-05-23
CN110511158A (zh) 2019-11-29
AU2012325768B2 (en) 2017-08-10
JP2017222648A (ja) 2017-12-21
JP2014530880A (ja) 2014-11-20
GEAP201913471A (en) 2019-10-25
DK2768796T3 (da) 2020-02-24
HUE048023T2 (hu) 2020-05-28
IL232139A (en) 2017-11-30
WO2013059788A1 (en) 2013-04-25
PL2768796T3 (pl) 2020-05-18
US20180230100A1 (en) 2018-08-16
AU2017254982A1 (en) 2017-11-23
IL232139A0 (en) 2014-05-28
US20160229805A1 (en) 2016-08-11
MX343288B (es) 2016-11-01
HK1201517A1 (en) 2015-09-04
NZ723880A (en) 2018-03-23
MX2014004583A (es) 2014-10-06
US9365516B2 (en) 2016-06-14
AU2012325768A1 (en) 2014-05-22
CA2852771A1 (en) 2013-04-25
NZ624328A (en) 2016-10-28
JP6208140B2 (ja) 2017-10-04
EA201490831A1 (ru) 2014-09-30
UA116876C2 (uk) 2018-05-25
ES2765013T3 (es) 2020-06-05
US9969692B2 (en) 2018-05-15
US20140256938A1 (en) 2014-09-11
KR20140088874A (ko) 2014-07-11
CA2852771C (en) 2019-11-26
TWI642650B (zh) 2018-12-01
TW201731812A (zh) 2017-09-16
BR112014009302B1 (pt) 2020-04-28
EP2768796A1 (en) 2014-08-27
ZA201402579B (en) 2015-03-25
TW201321342A (zh) 2013-06-01
IN2014CN02971A (https=) 2015-07-03
EA031485B1 (ru) 2019-01-31
TWI619694B (zh) 2018-04-01
PT2768796T (pt) 2020-02-21
GEP20207110B (en) 2020-05-25
EP2768796B1 (en) 2019-11-20
KR102075371B1 (ko) 2020-02-10

Similar Documents

Publication Publication Date Title
AR088483A1 (es) Proceso para preparar derivados de quinolina
AR091159A1 (es) Derivados de pirrolo[2,3-b]piridina y sintesis de los mismos
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
FR2975694B1 (fr) Procede de preparation de bis(fluorosulfonyl)imidure de lithium
CO7111275A2 (es) Inhibidores de dgat1 de éter cíclico de cabeza de puente
BR112018011518A2 (pt) método de produção de derivado de amida aromática
MX352470B (es) Disales de acido malonico y metodo para preparar dihaluros de malonilo.
EA201992421A1 (ru) Способ получения озанимода
MX2015015844A (es) Proceso para preparar compuestos n-sustituidos de acido 1h-pirazol-5-carboxilico y sus derivados.
EA201691102A1 (ru) Способ удаления soиз газа при помощи полиольного сложного раствора
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
PE20140917A1 (es) Sintesis de derivados de 2-carboxamida-cicloamino-urea
MX375447B (es) Proceso para fabricar haloacetamidas.
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
AR094652A1 (es) Preparación de sulfonamidas nematocidas
AR086848A1 (es) Procedimiento de sintesis y forma cristalina del hidrocloruro de 4-{3-[cis-hexahidrociclopenta[c]pirrol-2-(1h)-il]propoxi}benzamida asi como las composiciones farmaceuticas que la contienen
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
CL2014002029A1 (es) Método para preparar un compuesto de formula 1 mediante la reacción de adición de michael , usando agua o acido o una mezcla de los mismos como aditivo, entre un compuesto de formula 2 y un compuesto de formula 3 en presencia de polvo de cobre.
MX2018009831A (es) Proceso para preparar compuestos de aminotiolester y sus sales.
UY33879A (es) Proceso para la preparación de amidas del ácido pirazol carboxílico
RU2012114930A (ru) Способ получения ароматических аминосульфокислот
MX2015015346A (es) Procedimiento para la preparacion de intermediarios de acido boronico.
EA201591348A1 (ru) Опосредуемое dcc сочетание для получения галофената
AR110701A1 (es) Procesos para la preparación de compuestos pesticidas y compuestos intermediarios
AR101730A1 (es) Método para la preparación de imidazopiridazinas sustituidas e intermediario de dicho método

Legal Events

Date Code Title Description
FC Refusal